The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2023 | Key clinical trial updates from ASCO GI 2023
Rachna T. Shroff, MD, MS, University of Arizona College of Medicine, Tucson, AZ, provides an overview of her highlights from the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium, including results from the SPOTLIGHT trial (NCT03504397) in patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma, as well as NAPOLI-3 (NCT04083235) trial in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Additional highlights include findings from the SWOG 1815 trial (NCT03768414) in patients with biliary tract cancers, as well as advances in the role of ctDNA in colorectal cancer. This interview took place at the ASCO 2023 GI Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This has been an incredible GI ASCO. It’s a really exciting year. There’s a lot of data coming out every day. I have to say, as Chair Elect, I was able to kind of see what was going to be presented, both in the upper GI space with SPOTLIGHT coming out, in pancreas with NAPOLI coming out, in biliary with the GemCis ATEZO-BEV and SWOG 1815 coming out. It’s a really busy meeting...
This has been an incredible GI ASCO. It’s a really exciting year. There’s a lot of data coming out every day. I have to say, as Chair Elect, I was able to kind of see what was going to be presented, both in the upper GI space with SPOTLIGHT coming out, in pancreas with NAPOLI coming out, in biliary with the GemCis ATEZO-BEV and SWOG 1815 coming out. It’s a really busy meeting.The GALAXY data was published, and colon, of course. The ctDNA world is evolving at a ridiculous pace, and so we’re really starting to understand how to use ctDNA in colorectal cancer, and hopefully that will translate to other GI cancers. So it’s really, I think, an exciting meaning pretty much every day in terms of positive results that are going to be presented.
Read more...
